logo

For the Inventor, By the Inventor

Stockholm, Sweden

Anders Vahlne

USPTO Granted Patents = 12 

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 21(Granted Patents)


Location History:

  • Hovås, SE (2001)
  • Bâstard, SE (2008)
  • Båstad, SE (2008 - 2009)
  • Stockholm, SE (2002 - 2016)

Company Filing History:

goldMedal10 out of 35 
 
Tripep Ab
 patents
silverMedal2 out of 11 
 
Chrontech Pharma Ab
 patents

Years Active: 2001-2016

Loading Chart...
12 patents (USPTO):Explore Patents
1. 9284548 - High affinity adaptor molecules for redirecting antibody specifity (2016-03-15),
2. 9079962 - Glycosylated specificity exchangers (2015-07-14),
3. 8658179 - Glycosylated specificity exchangers (2014-02-25),
4. 8303956 - Glycosylated specificity exchangers (2012-11-06),
5. 7534435 - Glycosylated specificity exchangers (2009-05-19),
6. 7335359 - Glycosylated specificity exchangers (2008-02-26),
7. 7332166 - Glycosylated specificity exchangers (2008-02-19),
8. 7012129 - Antiviral composition comprising glycine amide (2006-03-14),
9. 6593455 - Tripeptide amides that block viral infectivity and methods of use thereof (2003-07-15),
10. 6537967 - Pentamer peptide amide, ALGPGNH2, which inhibits viral infectivity and methods of use thereof (2003-03-25),
11. 6455670 - Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof (2002-09-24),
12. 6258932 - Peptides that block viral infectivity and methods of use thereof (2001-07-10),

Title: The Innovative Contributions of Anders Vahlne

Introduction

Anders Vahlne, a prominent inventor based in Stockholm, Sweden, has made significant strides in the realm of biotechnology. With a remarkable portfolio of 12 patents, he has contributed to the advancement of therapeutic techniques and concepts that redirect the specificity of antibodies. His innovative work aims to address pressing medical challenges and improve treatments for various human diseases.

Latest Patents

Among his latest patents, two notable inventions stand out. The first one is focused on high affinity adaptor molecules designed for redirecting antibody specificity. This patent discloses methods for identifying molecules that can bind both a circulating antibody and a target molecule, effectively steering the immune response towards the desired target. The second patent involves glycosylated specificity exchangers, which pertains to ligand/receptor and antigen/antibody specificity exchangers incorporating saccharides or glycoconjugates. It details methods for creating these exchangers and showcases their potential for treating or preventing human diseases.

Career Highlights

Throughout his career, Anders has worked with respected organizations in the biotechnology sector. Notable companies include Tripep AB and Chrontech Pharma AB, where he has played a pivotal role in developing innovative solutions that leverage his expertise in molecular biology and immunology.

Collaborations

Anders Vahlne has collaborated with various distinguished professionals, including Matti Sällberg and Maria Perdomo. These partnerships have enriched his research and development initiatives, allowing for a diverse exchange of ideas and fostering innovation within the field.

Conclusion

With a strong foundation in biotechnology and a commitment to addressing medical challenges, Anders Vahlne stands out as a key inventor whose work holds the promise of advancing therapeutics. His latest patents exemplify his innovative spirit and dedication to improving healthcare solutions, solidifying his position as a leading figure in the field of invention.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…